Tenalisib is a potent and selective dual PI3K/ inhibitor that inhibited growth of B-cell lymphoma cell lines with a concomitant reduction in the downstream biomarker, pAKT.
For research use only. We do not sell to patients.
Name | Tenalisib |
---|---|
Iupac Chemical Name | (S)-2-(1-((7H-purin-6-yl)amino)propyl)-3-(3-fluorophenyl)-4H-chromen-4-one |
Synonyms | RP6530; RP6530; RP 6530 |
Molecular Formula | C23H18FN5O2 |
Molecular Weight | 415.43 |
Smile | O=C1C(C2=CC=CC(F)=C2)=C([C@@H](NC3=C4NC=NC4=NC=N3)CC)OC5=C1C=CC=C5 |
InChiKey | HDXDQPRPFRKGKZ-INIZCTEOSA-N |
InChi | InChI=1S/C23H18FN5O2/c1-2-16(29-23-19-22(26-11-25-19)27-12-28-23)21-18(13-6-5-7-14(24)10-13)20(30)15-8-3-4-9-17(15)31-21/h3-12,16H,2H2,1H3,(H2,25,26,27,28,29)/t16-/m0/s1 |
CAS Number | 1639417-53-0 or 1693773-94-2 |
Related CAS |
Packaging | Price | Availability | Purity | Shipping Time |
---|---|---|---|---|
Bulk | Enquiry | Enquiry | Enquiry |
Formulation | Solid powder |
---|---|
Purity | 98% |
Storage | -20 ºC for 3 years |
Solubility | Soluble in DMSO |
Handling | |
Shipping Condition | Shipped under ambient temperature |
HS Code |
Targets | |
---|---|
Mechanism | |
Cell study | |
Animal study | |
Clinical study |